Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

The development and assessment of biological treatments for children.

Smith EM, Foster HE, Beresford MW.

Br J Clin Pharmacol. 2015 Mar;79(3):379-94. doi: 10.1111/bcp.12406. Review.

2.

EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology.

Dixon WG, Carmona L, Finckh A, Hetland ML, Kvien TK, Landewe R, Listing J, Nicola PJ, Tarp U, Zink A, Askling J.

Ann Rheum Dis. 2010 Sep;69(9):1596-602. doi: 10.1136/ard.2009.125526.

PMID:
20525843
3.

Biologics in children's autoimmune disorders: efficacy and safety.

Breda L, Del Torto M, De Sanctis S, Chiarelli F.

Eur J Pediatr. 2011 Feb;170(2):157-67. doi: 10.1007/s00431-010-1238-z. Review.

PMID:
20556424
4.

Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry.

Mok CC, Chan KY, Lee KL, Tam LS, Lee KW; Hong Kong Society of Rheumatology..

Int J Rheum Dis. 2014 Dec;17 Suppl 3:1-8. doi: 10.1111/1756-185X.12264.

PMID:
24382315
5.

Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems.

Herrinton LJ, Curtis JR, Chen L, Liu L, Delzell E, Lewis JD, Solomon DH, Griffin MR, Ouellet-Hellstom R, Beukelman T, Grijalva CG, Haynes K, Kuriya B, Lii J, Mitchel E, Patkar N, Rassen J, Winthrop KL, Nourjah P, Saag KG.

Pharmacoepidemiol Drug Saf. 2011 Nov;20(11):1199-209. doi: 10.1002/pds.2196.

6.

Anti-TNF agents for paediatric psoriasis.

Sanclemente G, Murphy R, Contreras J, García H, Bonfill Cosp X.

Cochrane Database Syst Rev. 2015 Nov 24;(11):CD010017. doi: 10.1002/14651858.CD010017.pub2. Review.

PMID:
26598969
7.
8.

Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.

Singh JA, Hossain A, Tanjong Ghogomu E, Kotb A, Christensen R, Mudano AS, Maxwell LJ, Shah NP, Tugwell P, Wells GA.

Cochrane Database Syst Rev. 2016 May 13;(5):CD012183. doi: 10.1002/14651858.CD012183. Review.

PMID:
27175934
9.

Biologics and postbiologics: novel immunotherapeutics for the induction and maintenance of remission.

van Eden W, Lisse J, Prakken B, Albani S.

Drug Discov Today. 2010 Jan;15(1-2):71-7. doi: 10.1016/j.drudis.2008.12.010. Review.

PMID:
19162218
10.

Biologic agents for the treatment of juvenile rheumatoid arthritis: current status.

Carrasco R, Smith JA, Lovell D.

Paediatr Drugs. 2004;6(3):137-46. Erratum in: Paediatr Drugs. 2005;7(2):136. Carrasco, Ruy [added]; Smith, Judith A [added].

PMID:
15170361
11.

Biologics for the treatment of autoimmune renal diseases.

Holdsworth SR, Gan PY, Kitching AR.

Nat Rev Nephrol. 2016 Apr;12(4):217-31. doi: 10.1038/nrneph.2016.18. Review.

PMID:
26949177
12.

Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO).

Ruperto N, Martini A.

Arch Dis Child. 2011 Jun;96(6):596-601. doi: 10.1136/adc.2010.188946. Review.

PMID:
21317432
13.

[Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials].

Zhang Z, Schmitt J, Wozel G, Kirch W.

Med Klin (Munich). 2009 Feb 15;104(2):125-36. doi: 10.1007/s00063-009-1024-8. German.

PMID:
19242664
14.

Impact of the European paediatric legislation in paediatric rheumatology: past, present and future.

Ruperto N, Vesely R, Saint-Raymond A, Martini A; Paediatric Rheumatology International Trials Organisation (PRINTO)..

Ann Rheum Dis. 2013 Dec;72(12):1893-6. doi: 10.1136/annrheumdis-2013-204168.

PMID:
23962457
15.

New therapies under development for psoriasis treatment.

García-Pérez ME, Stevanovic T, Poubelle PE.

Curr Opin Pediatr. 2013 Aug;25(4):480-7. doi: 10.1097/MOP.0b013e328362c3f6. Review.

PMID:
23838833
16.

Principles of biological therapy in psoriasis.

Caca Biljanovska N, V'lckova Laskoska M.

Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2013;34(1):143-53. Review.

PMID:
23928807
17.

[Evidence of treatment of chronic inflammation in childhood and adolescence with biologics].

Huppertz HI, Lehmann HW.

Z Rheumatol. 2014 Dec;73(10):907-16. doi: 10.1007/s00393-014-1398-8. German.

PMID:
25479934
18.

Pharmacological treatment of children with gastro-oesophageal reflux.

Tighe M, Afzal NA, Bevan A, Hayen A, Munro A, Beattie RM.

Cochrane Database Syst Rev. 2014 Nov 24;(11):CD008550. doi: 10.1002/14651858.CD008550.pub2. Review.

PMID:
25419906
19.

Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters.

Schoot RA, Kremer LC, van de Wetering MD, van Ommen CH.

Cochrane Database Syst Rev. 2013 Sep 11;(9):CD009160. doi: 10.1002/14651858.CD009160.pub2. Review.

PMID:
24026801
20.

Biosimilar vs biological agents in rheumatology: When are biosimilar agents similar enough?

Lie G, Sciascia S, Cuadrado MJ.

Int Immunopharmacol. 2015 Aug;27(2):220-3. doi: 10.1016/j.intimp.2015.04.022. Review.

PMID:
25907240
Items per page

Supplemental Content

Support Center